Illumina’s Post

An image might be worth a thousand words, but a video can convey much more. At Acellera Therapeutics, we've created a video to simplify our complex small-molecule discovery process. Discover how our QuantumBind® platform, powered by AI and Quantum chemistry, is transforming drug discovery. Watch now and see innovation in action. For more information, visit: https://www.acellera.com. #DrugDiscovery #AI #QuantumChemistry #Innovation #Acellera

My simplified perspective on #AI in the #drug #discovery process based off of #BCG's 2022 Nature Reviews paper "AI in Small-Molecule Drug Discovery: A Coming Wave"? For a thorough analysis, please refer to "It’s Been a Decade of AI in the Drug Discovery Race. What’s Next?" by Andrii Buvailo, Ph.D. https://lnkd.in/eUdn3u96 https://lnkd.in/eKKVHzMY

𝐀𝐜𝐜𝐞𝐥𝐞𝐫𝐚𝐭𝐢𝐧𝐠 𝐃𝐫𝐮𝐠 𝐃𝐢𝐬𝐜𝐨𝐯𝐞𝐫𝐲 𝐰𝐢𝐭𝐡 𝐜𝐞𝐒𝐀𝐑: 𝐀 𝐁𝐫𝐞𝐚𝐤𝐭𝐡𝐫𝐨𝐮𝐠𝐡 𝐢𝐧 𝐈𝐧-𝐬𝐢𝐥𝐢𝐜𝐨 𝐒𝐜𝐫𝐞𝐞𝐧𝐢𝐧𝐠 In the ever-evolving field of drug discovery, speed and accuracy are crucial. The newly developed Connectivity Enhanced Structure Activity Relationship (ceSAR) framework is a game-changer, combining transcriptional signature connectivity with molecular docking to significantly enhance the efficiency of drug discovery and repurposing efforts. Built on the extensive LINCS library of transcriptional signatures, ceSAR integrates cheminformatics and virtual screening techniques to connect small molecules with their targets. The framework initially ranks candidate compounds based on their chemical similarity to LINCS analogs, which exhibit transcriptomic concordance with a target gene knockdown. This process is followed by a second phase where top candidates are rescored using docking simulations, leading to a consensus ranking that improves accuracy while drastically reducing false positives. In benchmarking tests, ceSAR has demonstrated its capability to reduce the computational time by several orders of magnitude compared to traditional docking methods, while also cutting down on false positives. This makes ceSAR a powerful tool for virtual screening, particularly in identifying inhibitors for complex targets such as BCL2A1, a key antiapoptotic protein involved in diseases like melanoma and preterm birth-associated inflammation. By leveraging both transcriptomic data and biophysical compatibility, ceSAR not only accelerates the identification of promising drug candidates but also democratizes drug discovery, making advanced screening tools more accessible to a broader range of researchers. Discover how ceSAR is transforming drug discovery and bringing us closer to personalized precision medicine: [https://lnkd.in/dWpGeBQG]. At Medvolt, we harness the power of generative AI, alongside other large language models (LLMs) and deep learning technologies, through our innovative platform 𝐌𝐞𝐝𝐆𝐫𝐚𝐩𝐡. 𝐅𝐞𝐞𝐥 𝐟𝐫𝐞𝐞 𝐭𝐨 𝐜𝐨𝐧𝐭𝐚𝐜𝐭 𝐮𝐬 𝐢𝐟 𝐲𝐨𝐮 𝐡𝐚𝐯𝐞 𝐚𝐧𝐲 𝐢𝐧𝐪𝐮𝐢𝐫𝐢𝐞𝐬 𝐨𝐫 𝐫𝐞𝐪𝐮𝐢𝐫𝐞 𝐚 𝐝𝐞𝐦𝐨𝐧𝐬𝐭𝐫𝐚𝐭𝐢𝐨𝐧. 𝐖𝐞'𝐫𝐞 𝐡𝐞𝐫𝐞 𝐭𝐨 𝐚𝐬𝐬𝐢𝐬𝐭 𝐲𝐨𝐮 𝐚𝐧𝐝 𝐩𝐫𝐨𝐯𝐢𝐝𝐞 𝐜𝐥𝐚𝐫𝐢𝐭𝐲. Visit our website: https://www.medvolt.ai or reach out to us via email: contact@medvolt.ai #DrugDiscovery #InSilicoScreening #Bioinformatics #PrecisionMedicine #PharmaceuticalResearch #MachineLearning

New blog! Discover how AI, machine learning, and in vitro assays are revolutionizing cardiotoxicity risk assessment in drug discovery. Explore our latest advancements in predicting cardiac risks, improving drug safety, and accelerating the development process. Check out the full blog here: https://hubs.ly/Q02SjWpg0 #AI #MachineLearning #DrugDiscovery #Cardiotoxicity

Artificial intelligence (AI) has made significant strides in biomedical research, showcasing its transformative potential in driving innovation within drug development. In the September issue of Med, Zhang et al. review the significant advancements in AI-assisted drug development, focusing on small molecules, RNA, and antibodies. The review highlights the challenge in obtaining approval for AI-conceived drugs and proposes leveraging large language models and diffusion models as solutions. The cover image captures two AI robots analyzing AI-generated drugs in a clinical environment, symbolizing AI’s transformative impact on drug discovery, development, and clinical trials. Explore the issue: https://lnkd.in/edzcV6Mp #ArtificialIntelligence #DrugDevelopment #DrugDiscovery #AIInMedicine

A fantastic representation of small-Molecule Discovery for GPCRs using MD simulations 👏

How AI and RNA Tech is Transforming Drug Discovery | Inside Atomic AI In this episode, we explore the cutting-edge intersection of AI and biotechnology with Raphael Townshend, founder and CEO of Atomic AI.

New blog! Discover how AI, machine learning, and in vitro assays are revolutionizing cardiotoxicity risk assessment in drug discovery. Explore our latest advancements in predicting cardiac risks, improving drug safety, and accelerating the development process. Check out the full blog here: https://hubs.ly/Q02SjSzR0 #AI #MachineLearning #DrugDiscovery #Cardiotoxicity

🚀 AI in Drug Discovery: A Breakthrough with Tx-LLM 🌟 AI's role in healthcare is expanding, and Tx-#LLM is a prime example of how it's revolutionizing drug discovery. Fine-tuned from #PaLM-2 and trained on diverse #datasets (molecules, proteins, cells, diseases), this model has pushed the boundaries of what AI can achieve. 📊 What makes #Tx-LLM unique? It excels in tasks where molecular data (like SMILES strings) are combined with text, outperforming state-of-the-art models in 43 out of 66 tasks! This combination of data allows AI to provide better predictions and insights, helping researchers accelerate drug development. 💡 Key takeaway: Tx-LLM’s success shows that language models fine-tuned for specific scientific tasks can outperform general AI in complex areas like chemistry. While there’s room for improvement, it’s a significant step toward AI-driven drug discovery, from gene identification to clinical trials. #AI #DrugDiscovery #HealthcareInnovation #MachineLearning #TxLLM #Biotech

Discover the Game-Changing Impact of 𝗚𝗲𝗻𝗲𝗿𝗮𝘁𝗶𝘃𝗲 𝗔𝗜 in Pharma ✅Accelerating Drug Discovery ✅Optimizing Clinical Trials ✅Simplifying Data Management. Experience how Generative AI revolutionizes the drug development process from identification to virtual screening, cutting costs and saving crucial time. By leveraging molecular generation, RNA sequencing, and protein prediction, businesses boost productivity by up to 25%, empowering researchers and analysts. Furthermore, streamlines trial designs, identifying patient subgroups efficiently. With seamless data management, extract vital insights from complex datasets, enhancing decision-making.  Embrace the future of Pharma innovation with Generative AI.  #generative #ai #pharmainnovation #clinicaltrials #datamanagement